KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Fulgent Genetics (FLGT) Enterprise Value (2016 - 2025)

Fulgent Genetics' Enterprise Value history spans 10 years, with the latest figure at -$341.4 million for Q4 2025.

  • For Q4 2025, Enterprise Value fell 30.2% year-over-year to -$341.4 million; the TTM value through Dec 2025 reached -$341.4 million, down 30.2%, while the annual FY2025 figure was -$341.4 million, 30.2% down from the prior year.
  • Enterprise Value for Q4 2025 was -$341.4 million at Fulgent Genetics, up from -$380.9 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$216.6 million in Q3 2024 and bottomed at -$578.3 million in Q1 2022.
  • The 5-year median for Enterprise Value is -$368.2 million (2021), against an average of -$385.8 million.
  • The largest annual shift saw Enterprise Value tumbled 1408.56% in 2021 before it soared 53.38% in 2024.
  • A 5-year view of Enterprise Value shows it stood at -$355.5 million in 2021, then plummeted by 47.11% to -$523.0 million in 2022, then increased by 18.37% to -$427.0 million in 2023, then surged by 38.6% to -$262.2 million in 2024, then plummeted by 30.2% to -$341.4 million in 2025.
  • Per Business Quant, the three most recent readings for FLGT's Enterprise Value are -$341.4 million (Q4 2025), -$380.9 million (Q3 2025), and -$297.9 million (Q2 2025).